jbp-485 and Body-Weight

jbp-485 has been researched along with Body-Weight* in 1 studies

Other Studies

1 other study(ies) available for jbp-485 and Body-Weight

ArticleYear
Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
    Bioorganic & medicinal chemistry letters, 2022, 01-15, Volume: 56

    Non-alcoholic steatohepatitis (NASH) is a serious form of non-alcoholic fatty liver disease (NAFLD) characterized by liver steatosis with lobular inflammation, hepatocyte injury and pericellular fibrosis. JBP485 is a hydrophilic dipeptide with protective effects on liver through alleviation of oxidative stress and inhibition of hepatocyte apoptosis and ICAM-1 expression. Vitamin E (VE), as a powerful biological antioxidant, exerts a certain protective effect on cell membranes and lipoproteins from lipid peroxidation. In this study, on the basis of the structural characteristics of two agents, the prodrug form target of JBP485 and VE (JBP485-VE) was designed and synthesized via succinic acid linker. The synthesized compound significantly reduced the degree of inflammation and fibrosis according to hematoxylin-eosin (H&E) and sirius red staining assay for the liver tissue in CCl

    Topics: Animals; Body Weight; Carbon Tetrachloride; Dose-Response Relationship, Drug; Drug Design; Fibrosis; Humans; Inflammation; Liver; Mice; Molecular Structure; Non-alcoholic Fatty Liver Disease; Organ Size; Peptides, Cyclic; Prodrugs; Structure-Activity Relationship; Vitamin E

2022